ARK Genomic Revolution ETF (ARKG) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 2.76: the stock has moved about 176% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerARK Genomic Revolution ETF (ARKG) trades at $40.27. ARK Genomic Revolution ETF (ARKG) is an actively managed fund focusing on companies involved in the genomics revolution. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for ARKG: ARKG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
ARK Genomic Revolution ETF (ARKG) Financial Services Profile
ARK Genomic Revolution ETF (ARKG) is an actively managed ETF targeting companies at the forefront of the genomics revolution. The fund invests across multiple sectors, both domestically and internationally, seeking long-term capital appreciation through exposure to innovative genomic technologies and advancements. It offers investors a focused approach to capitalize on the growth potential within the genomics space.
What Is the Investment Thesis for ARKG?
ARKG's investment thesis centers on the long-term growth potential of companies involved in the genomics revolution. The fund's value drivers include the increasing adoption of genomic sequencing, gene editing technologies, and personalized medicine. As of March 2026, the genomics market is projected to continue its expansion, driven by technological advancements and decreasing sequencing costs. ARKG's active management allows it to adapt to the evolving landscape, capitalizing on emerging opportunities and mitigating risks. A key metric is the fund's exposure to companies with high growth rates in revenue and earnings, reflecting their leadership in the genomics space. The fund's success depends on its ability to identify and invest in companies that are driving innovation and disrupting traditional industries. The ongoing catalysts include advancements in CRISPR technology, increased regulatory approvals for gene therapies, and the expansion of genomic applications in healthcare and agriculture. The potential risks involve regulatory hurdles, competition from other genomics companies, and market volatility.
Based on FMP financials and quantitative analysis
ARKG Key Highlights
ARKG's focus on genomics provides exposure to a high-growth sector with transformative potential.
- The fund's active management allows for dynamic portfolio adjustments to capitalize on emerging opportunities.
- ARKG invests in both domestic and foreign companies, offering diversification across geographies.
- The ETF structure provides investors with a liquid and transparent way to access the genomics market.
- ARKG's investment strategy is driven by in-depth research and analysis of companies involved in the genomics revolution.
Who Are ARKG's Competitors?
ARKG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CCMG CCM Global Equity ETF | $32.90 | -0.42% | $1.02B | — |
| DFIP Dimensional - Inflation-Protected Securities ETF | $39.23 | +0.15% | $1.13B | — |
| FMAY FT Vest U.S. Equity Buffer ETF - May | $54.98 | -1.36% | $1.46B | — |
| IYE iShares U.S. Energy ETF | $64.13 | -0.74% | $1.81B | — |
| PAUG Innovator U.S. Equity Power Buffer ETF | $45.16 | -1.20% | $882M | — |
| BLK BlackRock, Inc. | $1169.21 | -0.97% | $181B | 59 5-pillar |
| BX Blackstone Inc. | $115.71 | -0.66% | $143B | 85 5-pillar |
| BAM Brookfield Asset Management | $50.37 | +0.22% | $80.5B | 79 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARKG's Key Strengths?
Focus on a high-growth sector with transformative potential.
- Active management allows for dynamic portfolio adjustments.
- Diversification across domestic and foreign companies.
- Strong brand recognition within the thematic ETF space.
What Are ARKG's Weaknesses?
High beta of 2.76 indicates higher volatility compared to the market.
- Concentrated focus on genomics may lead to sector-specific risks.
- Actively managed funds may underperform the market due to management decisions.
What Are the Key Risks for ARKG?
Regulatory hurdles and ethical concerns surrounding gene editing and personalized medicine.
- Competition from other genomics companies and ETFs.
- Market volatility and economic downturns impacting the genomics sector.
- Technological obsolescence and disruption within the genomics sector.
What Are ARKG's Competitive Advantages?
- First-mover advantage in focusing on the genomics revolution.
- Expertise in identifying and investing in innovative genomics companies.
- Strong brand recognition within the thematic ETF space.
What Does ARKG Do?
ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund (ETF) that focuses on companies involved in the genomics revolution. Launched with the goal of capturing long-term growth, ARKG invests primarily, with at least 80% of its assets, in equity securities of both domestic and foreign companies. The fund spans multiple sectors, identifying firms that are leading innovation and development in genomic sequencing, gene editing, targeted therapeutics, bioinformatics, and personalized medicine. ARKG provides investors with a vehicle to access the potential of genomic advancements, which are expected to transform healthcare, agriculture, and other industries. The fund’s investment strategy involves identifying companies that are not only currently contributing to the genomics revolution but also those poised to benefit from future advancements. By actively managing the portfolio, ARKG aims to capitalize on emerging opportunities and navigate the evolving landscape of the genomics sector. The fund’s holdings include companies of various sizes, from established players to emerging growth companies, reflecting the breadth of the genomics ecosystem. ARKG's investment approach is driven by in-depth research and analysis, seeking to identify companies with strong growth potential and competitive advantages within the genomics space. The ETF offers a diversified approach to investing in genomics, mitigating some of the risks associated with investing in individual companies. As of 2026, ARKG continues to be a prominent ETF for investors seeking exposure to the genomics revolution.
What Products and Services Does ARKG Offer?
- Invests in companies involved in genomic sequencing.
- Targets firms developing gene editing technologies.
- Focuses on companies advancing targeted therapeutics.
- Includes businesses engaged in bioinformatics.
- Invests in companies involved in personalized medicine.
- Actively manages a portfolio of domestic and foreign equity securities.
- Seeks long-term capital growth through exposure to the genomics revolution.
How Does ARKG Make Money?
- Generates revenue through management fees charged on assets under management (AUM).
- Aims to provide investors with exposure to the genomics revolution.
- Actively manages the portfolio to capitalize on emerging opportunities.
What Industry Does ARKG Operate In?
ARKG operates within the asset management industry, specifically focusing on the genomics sector. The genomics market is experiencing rapid growth, driven by technological advancements, decreasing sequencing costs, and increasing applications in healthcare, agriculture, and other industries. The competitive landscape includes other ETFs and investment funds that focus on genomics or related sectors. ARKG differentiates itself through its active management approach and its focus on companies that are driving innovation in the genomics space. The fund's success depends on its ability to identify and invest in companies with strong growth potential and competitive advantages.
Who Are ARKG's Key Customers?
- Individual investors seeking exposure to the genomics sector.
- Institutional investors looking for long-term growth opportunities.
- Financial advisors seeking to diversify client portfolios.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
ARKG Financials
Bull Case vs Bear Case
Bull Case
- Focus on a high-growth sector with transformative potential.
- Active management allows for dynamic portfolio adjustments.
- Diversification across domestic and foreign companies.
- Strong brand recognition within the thematic ETF space.
Bear Case
- High beta of 2.76 indicates higher volatility compared to the market.
- Concentrated focus on genomics may lead to sector-specific risks.
- Actively managed funds may underperform the market due to management decisions.
- Potential: Regulatory hurdles and ethical concerns surrounding gene editing and personalized medicine.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ARKG Latest News
-
Cathie Wood Trims EV Stock and Makes a Move on Driverless Trucks
GuruFocus.com · Nov 19, 2026
-
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
24/7 Wall St. · Nov 2, 2026
-
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Stocktwits · Oct 31, 2026
-
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
Motley Fool · Oct 18, 2026
ARKG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ARKG.
Price Targets
Wall Street price target analysis for ARKG.
ARKG MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ARKG; grades run from A+ (80-100) to F (below 30).
Latest News
Cathie Wood Trims EV Stock and Makes a Move on Driverless Trucks
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
ARK Genomic Revolution ETF Financials Stock: Key Questions Answered
What do analysts say about ARKG stock?
Generally, analysts may consider factors such as the fund's expense ratio, tracking error, and portfolio composition when evaluating its performance. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Data provided for informational purposes only.
- This dossier is based on limited information and should not be considered investment advice.